NYSE Arca · NRXS
Neuraxis, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NRXS: Nov 09, 2026
Neuraxis, Inc. Common Stock is expected to report earnings on 11/09/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.24.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Dec 2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Zacks · The Motley Fool- BNK Invest · Oct 9, 1:41 PM EDTFriday 10/9 Insider Buying Report: FEAM, NRXSAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At 5E Advanced Materials, a filing with the SEC revealed that on Thursday, Chief Ex
- RTTNews · Sep 16, 2:57 PM EDTBiotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA(RTTNews) – Biotech stocks were in focus Wednesday following a series of company updates, including Tempest Therapeutics' new in vivo CAR-T licensing deal, DataMEDS AI's Helomics acquisition, expanded coverage for NeurAxis' PENFS therapy and MAIA Biotechnology's first U.S. patien
- RTTNews · Sep 16, 10:40 AM EDTNeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up(RTTNews) – NeurAxis, Inc. (NRXS) has secured a significant medical coverage milestone as a major national health insurer expanded coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, adding access for approximately 18 million additional members acros
- Zacks · Sep 15, 11:11 AM EDTNeuraxis Gains Nearly 137% in a Year: What's Driving the Stock?NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.
- Zacks · Sep 12, 1:51 AM EDTIs Kodak having a "Kodak moment?" 2 watchlist stocks.KODK and NRXS are worth watching for their growth.
- Zacks · Aug 14, 11:42 AM EDTNRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin UpNeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
- The Motley Fool · Aug 11, 9:28 PM EDTNeurAxis (NRXS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 11, 8:19 AM EDTNeurAxis Posts Record Q2 2026 Results On PENFS Growth(RTTNews) – NeurAxis, Inc. (NRXS), a medical technology company focused on neuromodulation therapies, reported financial results for the second quarter ended June 30, 2026, showing strong revenue growth and improved operating metrics compared to the prior year.
- Zacks · May 15, 12:23 PM EDTNeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/YNRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.
- Zacks · May 5, 6:34 AM EDTThe Zacks Analyst Blog Highlights Alphabet, Walmart, Micron Technology and NeurAxisAlphabet, Walmart and Micron lead Zacks research as AI growth, retail strength and memory demand drive performance, while risks linger.
- Zacks · May 4, 4:11 PM EDTTop Stock Reports for Alphabet, Walmart & MicronAlphabet rides AI-driven growth across Search, Cloud and subscriptions, but rising spending, debt and legal risks temper near-term flexibility.
- Fintel · Apr 28, 3:46 AM EDTNeurAxis (NRXS) Price Target Increased by 29.41% to 11.22The average one-year price target for NeurAxis (NYSEAM:NRXS) has been revised to $11.22 / share. This is an increase of 29.41% from the prior estimate of $8.67 dated April 12, 2026. The price target is an average of many targets provided by analysts. The lates
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Neuraxis, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.